{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:55:12Z","timestamp":1772726112478,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ygyno.2022.12.023","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T23:47:53Z","timestamp":1673048873000},"page":"46-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level \u2013 A Memorial Sloan Kettering Cancer Center study"],"prefix":"10.1016","volume":"170","author":[{"given":"Ryan M.","family":"Kahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"McMinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Effi","family":"Yeoshoua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Boerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Long Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.12.023_bb0005","series-title":"Cancer Facts & Figures 2022","author":"American Cancer Society","year":"2022"},{"issue":"2","key":"10.1016\/j.ygyno.2022.12.023_bb0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","article-title":"Evolution of surgical treatment paradigms for advanced stage ovarian cancer: redefining \u2018optimal\u2019 residual disease","volume":"125","author":"Chang","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.12.023_bb0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.023_bb0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2018.08.014","article-title":"Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival?","volume":"151","author":"Tseng","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.12.023_bb0025","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1006\/gyno.2001.6312","article-title":"What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?","volume":"82","author":"Eisenkop","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.023_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2017.01.029","article-title":"Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible","volume":"145","author":"Wallace","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.12.023_bb0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.12.023_bb0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","article-title":"Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center","volume":"140","author":"Mueller","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2022.12.023_bb0045","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/cncr.22561","article-title":"Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis","volume":"109","author":"Bristow","year":"2007","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2022.12.023_bb0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejso.2008.01.005","article-title":"Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients","volume":"35","author":"Colombo","year":"2009","journal-title":"Eur. J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.12.023_bb0055","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3802\/jgo.2015.26.4.336","article-title":"Role of aggressive surgical cytoreduction in advanced ovarian cancer","volume":"26","author":"Chang","year":"2015","journal-title":"J. Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.023_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2015.10.025","article-title":"Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer","volume":"140","author":"Kumar","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.023_bb0065","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ygyno.2020.07.101","article-title":"Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: a Memorial Sloan Kettering Cancer Center Team Ovary study","volume":"159","author":"Boerner","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.12.023_bb0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2009.09.047","article-title":"Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients","volume":"116","author":"Diaz","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.12.023_bb0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","article-title":"FIGO\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication","volume":"26","author":"Prat","year":"2015","journal-title":"J. Gynecol. Oncol."},{"issue":"9990","key":"10.1016\/j.ygyno.2022.12.023_bb0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet."},{"issue":"12","key":"10.1016\/j.ygyno.2022.12.023_bb0085","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2022.12.023_bb0090","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2022.12.023_bb0095","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl. Cancer Inst. Monogr."},{"issue":"4","key":"10.1016\/j.ygyno.2022.12.023_bb0100","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.12.023_bb0105","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2022.12.023_bb0110","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","volume":"2011","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.ygyno.2022.12.023_bb0115","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"3 Pt 1","key":"10.1016\/j.ygyno.2022.12.023_bb0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/gyno.2000.5926","article-title":"A critique of surgical cytoreduction in advanced ovarian cancer","volume":"78","author":"Covens","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"2 Pt 2","key":"10.1016\/j.ygyno.2022.12.023_bb0125","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0090-8258(03)00342-1","article-title":"Future directions in the surgical management of ovarian cancer","volume":"90","author":"Berman","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"34","key":"10.1016\/j.ygyno.2022.12.023_bb0130","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1200\/JCO.2005.02.1287","article-title":"Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial","volume":"23","author":"Crawford","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.023_bb0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.12.023_bb0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2007.02.026","volume":"106","author":"Wimberger","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2022.12.023_bb0145","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1245\/s10434-017-6051-8","article-title":"A review of thoracic and mediastinal cytoreductive techniques in advanced ovarian cancer: extending the boundaries","volume":"24","author":"Nasser","year":"2017","journal-title":"Ann. Surg. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822020236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822020236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:50:01Z","timestamp":1715820601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822020236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":29,"alternative-id":["S0090825822020236"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.12.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level \u2013 A Memorial Sloan Kettering Cancer Center study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}